2011 Accepted Abstracts

Please note that abstracts have not been edited by PAINWeek staff for content, style, or accuracy, and are displayed as input by each submitter.

1. Open-label, open-ended study of the safety of diclofenac sodium topical solution for management of osteoarthritis: characterization of gastrointestinal adverse events
Charles Argoff1, Jeff Patrick2, Zev Shainhouse3
1Albany Medical College, Albany, NY, USA, 2Covidien, Hazelwood, MO, USA, 3Consultant, Toronto, ON, Canada
2. Open-label, open-ended study of the safety of diclofenac sodium topical solution for management of osteoarthritis: characterization of application-site adverse events
Zev Shainhouse1, Jeff Patrick2, Charles Argoff3
1Consultant, Toronto, ON, Canada, 2Covidien, Hazelwood, MO, USA, 3Albany Medical College, Albany, NY, USA
3. Evaluation of the current practices for managing postoperative pain and characterization of patients undergoing total knee or hip arthroplasty in a real-world setting
Carmen Kirkness1,5, Carrie McAdam-Marx2, Sudhir Unni2, Jason Young2, Xiangyang Ye2, Arthi Chandran4, Da-In Kim4, Junji Lin2, Christopher Peters3, Carl Asche2,5
1Department of Physical Therapy, College of Health, University of Utah, Salt Lake City, UTAH, USA, 2Department of Pharmacotherapy, University of Utah, Salt Lake City, UTAH, USA, 3Department of Orthopaedics, School of Medicine, University of Utah, Salt Lake City, UTAH, USA, 4Pfizer, Inc., New York, NEW YORK, USA, 5University of Illinois College of Medicine, Peoria, ILLINOIS, USA
4. Observation of improved adherence with ongoing urine drug testing in patients with chronic pain
David Yee1, Michelle Hughes1, Alexander Guo1, Stephanie Tse1, Neveen Barakat1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5
1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, USA, 2Doris A. Howell Palliative Care Service, La Jolla, California, USA, 3University of California Department of Pediatrics, Rady Children's Hospital-San Diego, San Diego, California, USA, 4Millennium Research Institute, San Diego, California, USA, 5University of California Department of Pathology and Laboratory Medicine, San Diego, California, USA
5. A novel diagnostic examination of the lumbar adhesion arachnoiditis by MRI scanning in supine and prone positions
Kenji Azuma, Masahiko Sumitani, Takamichi Kogure, Hiroshi Sekiyama, Yoshitsugu Yamada
Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan
6. The conversion of hydrocodone to hydromorphone and norhydrocodone comparison in subjects with chronic pain
Neveen Barakat1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5
1University of California, San Diego (UCSD), Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, LA Jolla, CA, USA
7. Dose-proportionality, relative bioavailability, and effects of food on bioavailability of an immediate-release oxycodone HCl tablet designed to discourage tampering
Almasa Bass1, Kenneth Somerville1, Robert Rolleri1, Glenn Pixton1, Jeffrey Stark2, Cynthia Zamora3, Mark Leibowitz3
1Pfizer Inc., Cary, NC, USA, 2Worldwide Clinical Trials Drug Development Solutions, Austin, TX, USA, 3Worldwide Clinical Trials Drug Development Solutions, San Antonio, TX, USA
8. Daily average consumption of oxycodone CR and oxymorphone ER before and after the introduction of reformulated oxycodone CR
R. Amy Puenpatom1, Kent Summers1, Robert Garvin1, Larry Ma1, Sheryl L. Szeinbach2, Rami Ben-Joseph1
1Endo Pharmaceuticals Inc., Chadds Ford, PA, USA, 2Ohio State University, College of Pharmacy, Columbus, OH, USA
9. A viable methodology for assessing the onset of treatment for low back pain
Jerrold Petrofsky1, Lee Berk1, Gurinder Bains1, Geraldine Doyle2, Shijie Chen2, Lisa Baird2, Paul Desjardins2, Jill Stark2
1Loma Linda University, Department of Physical Therapy, Loma Linda, CA, USA, 2Pfizer Consumer Healthcare, Madison, NJ, USA
10. A posthoc pooled data analysis to evaluate the gastrointestinal tolerability profile of tapentadol extended release (ER) vs oxycodone controlled release (CR) in patients ≥75 years of age
David Biondi1, Jim Xiang2, Mila Etropolski2, Bruce Moskovitz1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA
11. A posthoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies
David Biondi1, Jim Xiang2, Mila Etropolski2, Bruce Moskovitz1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA
12. Treatment of painful diabetic peripheral neuropathy in the nursing home: prevalence of the disease and conformance with a new evidence-based guideline
Frank Breve
Mid Atlantic PharmaTech Consultants, LLC, Ventnor, New Jersey, USA
13. Initial findings on abuse rates and routes of administration following introduction of reformulated OxyContin® in a sentinel surveillance system of patients in substance use treatment
Theresa Cassidy1, Paul Coplan2, Ryan Black1, Howard Chilcoat2, Simon Budman1, Stephen Butler1
1Inflexxion, Inc., Newton, MA, USA, 2Purdue Pharma L.P., Stamford, CT, USA
14. Sphygmomanometry-evoked allodynia for the identification of fibromyalgia patients
Arthi Chandran1, Cheryl Coon2, Susan Martin2, Lori McLeod2, Theresa Gilligan2, Lesley Arnold3
1Pfizer Inc., New York, NY, USA, 2RTI Health Solutions, Ann Arbor, MI, USA, 3University of Cincinnati College of Medicine, Cincinnati, OH, USA
15. An aid to guide primary care physicians in the differential diagnosis of fibromyalgia
Lesley Arnold1, Arthi Chandran2, Susan Martin3
1University of Cincinnati College of Medicine, Cincinnati, OH, USA, 2Pfizer Inc., New York, NY, USA, 3RTI Health Solutions, Ann Arbor, MI, USA
16. Evaluation of safety and efficacy of LEVADEX® (MAP0004) in treating acute menstrual migraine
Curtis P. Schreiber1, Shashidhar H. Kori2, Sylvia M. Lucas3, Scott W. Borland2, Min Wang2, Bin Hu2, Jan L. Brandes4, Susy Chen2
1Headache Care Center, Primary Care Network, Springfield, MO, USA, 2MAP Pharmaceuticals, Inc., Mountain View, CA, USA, 3University of Washington Medical Center, Seattle, WA, USA, 4Nashville Neuroscience Group, PC, Nashville, TN, USA
17. A long-term open-label study assessing the safety and tolerability of LEVADEX® orally inhaled dihydroergotamine in adult migraineurs
Don Kellerman, Jean Chang, Shashidhar Kori, Susy Chen
MAP Pharmaceuticals, Inc., Mountain View, CA, USA
18. Pain Education School: findings from year one of an "informational healing" program
David Cosio, Erica Hugo, Ronald Albrecht
Anesthesiology Service/Pain Clinic, Jesse Brown VA Medical Center, Chicago, IL, USA
19. An "informational" healing program: introduction to the Pain Education School program at Jesse Brown VA Medical Center
David Cosio, Erica Hugo, Ronald Albrecht
Anesthesiology Service/Pain Clinic, Jesse Brown VA Medical Center, Chicago, IL, USA
20. The medical borderline: personality characteristics that promote increased risk of opioid misuse
Geralyn Datz1, Melissa Bonnell2, Toni Merkey2, Todd Sitzman3
1Forrest General Hospital, Hattiesburg, MS, USA, 2University of Southern Mississippi, Hattiesburg, MS, USA, 3Advanced Pain Therapy, PLLC, Hattiesburg, MS, USA
21. Test-Retest reliability of clinical sensory testing for sensorimotor polyneuropathy
Joseph O. DiDuro, Thomas J. Burke
Neuropathy Treatment Centers of America, Phoenix, AZ, USA
22. A prospective study of changes in pain numeric rating scale with physiotherapy treatment for neuropathic pain
Joseph O. DiDuro, Thomas Burke
Neuropathy Treatment Centers of America, Phoenix, AZ, USA
23. A randomized, double-blind, placebo-controlled discontinuation study of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment
Philip Mease1, Yimin Ma2, Arlene Baldecchi2, Robert H. Palmer2, Joel M. Trugman2, Ian D'Souza2
1Seattle Rheumatology Associates and Swedish Medical Center, Seattle, Washington, USA, 2Forest Research Institute, Jersey City, New Jersey, USA
24. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia
Lesley Arnold1, Allan Spera2, Arlene Baldecchi2, Yong Wang2, Ian D'Souza2
1University of Cincinnati College of Medicine, Cincinnati, USA, 2Forest Research Institute, Jersey City, USA
25. Assessing concomitant use of oxycodone formulations with known strong cytochrome P450 (CYP) 2D6 inhibitors in patients with chronic pain
Natalie M. Elder1, Rabia S. Atayee1,2, Joseph D. Ma1,2, Bookie M. Best1,3, Amadeo J. Pesce4,5
1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, La Jolla, CA, USA, 3University of California San Diego Department of Pediatrics; Rady's Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5University of California San Diego Department of Pathology, La Jolla, CA, USA
26. Perceiving pain in oneself and others: the influence of perspective and priming
Samantha R. Fashler1, Kalie N. McCrystal1, Daniel Jones1, Judith Versloot2, Kenneth D. Craig1
1University of British Columbia, Vancouver, BC, Canada, 2University of Toronto, Toronto, ON, Canada
27. Perceiving pain in sports injuries: behavioral, contextual and cognitive factors
Kalie N. McCrystal1, Samantha R. Fashler1, Judith Versloot2, Kenneth D. Craig1
1University of British Columbia, Vancouver, British Columbia, Canada, 2University of Toronto, Toronto, Ontario, Canada
28. Prescription adherence among chronic pain patients: does monitoring according to the SAFE USE treatment monitoring program clinical guidelines for chronic opioid therapy improve patient adherence?
B. Baker Fore1
1The Wellness Center, Ardmore, OK, USA, 2Mercy Memorial Hospital, Ardmore, OK, USA
29. Participation in a regional hydromorphone safety initiative
Maria Foy, Maria Doll Shaw, Robert Giannini
Abington Memorial Hospital, Abington, PA, USA
30. When is more too much? A case of opioid induced neurotoxity
Maria Foy, Aalap Patel
Abington Memorial Hospital, Abington, PA, USA
31. Safety of diclofenac sodium topical solution compared with oral diclofenac for osteoarthritis of the knee in patients aged ≥65 years: pooled analysis from two controlled trials
Sanford Roth1, Philip Fuller1
1Arizona State University, Phoenix, AZ, USA, 2Covidien, Hazelwood, MO, USA
32. Efficacy of diclofenac sodium topical solution compared with oral diclofenac: a by-question analysis of 3 WOMAC ® dimensions in patients with osteoarthritis of the knee
Sanford Roth1, Philip Fuller2
1Arizona State University, Phoenix, AZ, USA, 2Covidien, Hazelwood, MO, USA
33. Assessment of chronic pain, impact on quality of life, and medication use utilizing a patient questionnaire
Dean Gianarkis1, Beth Vanderheyden1, Scott E. Glosner1, Maureen L. Blattner2, Peggy Lotkowictz3, Therese Cardosi4
1Pfizer, Inc., New York, NY, USA, 2Arthritis Foundation, West Allis, Wisconsin, Upper Midwest Region, USA, 3Arthritis Foundation, Iselin, NJ, Northeast Region, USA, 4Arthritis Foundation, Kankakee, IL, USA
34. Bioavailability of crush-resistant oxymorphone extended-release 40 mg with ethanol under fasted conditions
William Fiske, Janet Jobes, Qinfang Xiang, Errol Gould, Irma Benedek
Endo Pharmaceuticals Inc., Chadds Ford, PA, USA
35. Bioequivalence of crush-resistant oxymorphone extended release 40 mg and oxymorphone extended release 40 mg under fed conditions
Irma Benedek, Janet Jobes, Qinfang Xiang, Errol Gould, William Fiske
Endo Pharmaceuticals Inc., Chadds Ford, PA, USA
36. Effectiveness and safety of lidocaine 5% patch as add-on treatment in patients with allodynia caused by postherpetic neuralgia, diabetic neuropathy, or low back pain
Srinivas Nalamachu1, Matthew S. Wieman2, Errol M. Gould2
1International Clinical Research Institute, Overland Park, KS, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, PA, USA
37. Efficacy, safety, and tolerability of HZT-501, including users of low-dose aspirin (LDA), a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials
Michael Weinblatt1, Mark Genovese2, Alan Kivitz3, Al Bello4, Amy Grahn5, Michael Schiff6
1Harvard Medical School Division of Rheumatology, Boston, MA, USA, 2Stanford University, Stanford, CA, USA, 3Altoona Center for Clinical Research, Altoona, PA, USA, 4Illinois Bone and Joint Institute, Glenview, IL, USA, 5Horizon Pharma USA, Inc, Northbrook, IL, USA, 6University of Colorado, Denver, CO, USA
38. Long-term safety of an NSAID with built-in gastroprotection for treatment of pain and inflammation related to OA and RA: comparative results from blinded and open-label one- year safety trials of a single-tablet combination of ibuprofen-famotidine
Jay Goldstein1, Sharad Lakhanpal2, Stanley Cohen2, Al Bello3, Amy Grahn4, Alan Kivitz5
1University of Illinois, Chicago, IL, USA, 2Metroplex Clinical Research Center, Dallas, TX, USA, 3Illinois Bone and Joint Institute, Morton Grove, IL, USA, 4Horizon Pharma USA, Inc, Northbrook, IL, USA, 5Altoona Center for Clinical Research, Altoona, PA, USA
39. An innovative Risk Evaluation and Mitigation Strategy (REMS) for Abstral, a transmucosal immediate-release fentanyl (TIRF) product
Greg Guillory1, Anthony G. Oladipo1, Bridget O'Mahony2, Kristina Crockett3, Julian Howell1
1ProStrakan, Inc., Bedminster, New Jersey, USA, 2ProStrakan Group Plc., Galashiels TD1 1QH, UK, 3RelayHealth Pharmacy, Atlanta, Georgia, USA
40. Inter- and intrasubject variability of urinary norbuprenorphine to buprenorphine metabolic ratios in pain patients
Alexander Y. Guo1, Rabia S. Atayee1,2, Joseph D. Ma1,2, Brookie M. Best1,3, Amadeo J. Pesce4,5
1University of California, San Diego, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA
41. Gastrointestinal tolerability during conversion and titration with once-daily hydromorphone ER (OROS hydromorphone ER) in opioid-tolerant patients with chronic low back pain
Martin Hale1, Srinivas Nalamachu2, Arif Khan3
1Gold Coast Research, LLC., Weston, FL, USA, 2International Clinical Research Institute, Overland Park, KS, USA, 3Northwest Clinical Research Center, Bellevue, WA, USA
42. Perceived pain, disability, and psychometric measures in neuropathic vs nociceptive pain
Meryem Saracoglu1,2, Joseph R. Graciosa1, Maxine M. Kuroda1, R. Norman Harden1,2
1Rehabilitation Institute of Chicago, Chicago, IL, USA, 2Northwestern University Feinberg School of Medicine, Department of Physical Medicine & Rehabilitation, Chicago, IL, USA
43. Providing optimal care to the chronic pain patient in the community pharmacy: a patient survey
Erron Swick, Chris Herndon
Southern Illinois University Edwardsville, Edwardsville, IL, USA
44. Knowledge of chronic pain: an analysis of health literacy
Jake Griffin, Radhika Devraj, Chris Herndon
Southern Illinois University Edwardsville, Edwardsville, IL, USA
45. Oral local anesthesia successfully ameliorated neuropathic pain in an upper limb, suggesting pain alleviation through neural plasticity within the central nervous system: a case report
Jun Hozumi1, Masahiko Sumitani1, Arito Yozu2, Toshiya Tomioka1, Hiroshi Sekiyama1, Satoru Miyauchi3, Yoshitsugu Yamada1
1Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan, 2Department of Rehabilitation Medicine, The University of Tokyo, The Graduate School of Medicine, Tokyo, Japan, 3Kobe Advanced ICT Research Center, National Institute of Information and Communications Technology, Kobe, Japan
46. Donepezil could reverse pregabalin/gabapentin-induced somnolence in patients with neuropathic pain
Kiyoshi Ikegami1, Masahiko Sumitani1, Takamichi Kogure1, Kenji Azuma1, Hiroshi Sekiyama1, Satoru Miyauchi2, Yoshitsugu Yamada2
1Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan, 2CREST brain function imaging team, Kobe Advanced ICT Research Center, National Institute of Information and Communications Technology, Hyogo, Japan
47. Analysis of Pain Management Team patient survey
Christine Kahley, Christine Higgins, Alisha Cain
York Hospital, York, PA, USA
48. Impact of an electronic medication error reporting system in a hospice organization
Mina Kim1, Mary Lynn McPherson2, Elizabeth Kopochis3, Sheila Weiss2
1University of Washington Medical Center, Seattle, WA, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3Seasons Hospice and Palliative Care, Philadelphia, PA, USA
49. Medication error reporting practices in hospice
Mina Kim1, Mary Lynn McPherson1
1University of Washington Medical Center, Seattle, WA, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA
50. Incidence of hydromorphone associated opioid-induced neurotoxicity
Justin Kullgren1,2, Vy Le2, Warren Wheeler1
1Roseman University of Health Sciences, Henderson, NV, USA, 2Nathan Adelson Hospice, Las Vegas, NV, USA
51. Comparison of oral fluid and urine drug testing in a population of those with chronic pain
Sergey Latyshev, David Masters-Moore, Charles Mikel Millennium Research Institute, San Diego, CA, USA
52. Using quantitative urine drug levels to monitor adherence to chronic opioid therapy: a comparison across two pain populations
Russell Portenoy1, Harry Leider2, Ariel Linden3, Kathryn Bronstein2, Laura Dhingra1, Helena Knotkova1, Ricardo Cruciani1
1Beth Israel Medical Center, New York, NY, USA, 2Ameritox, Ltd., Baltimore, MD, USA, 3Linden Consulting Group, LLC, Portland, OR, USA
53. Healthcare provider perspectives on managing pain in the geriatric population
Salma Lemtouni1, Kevin Zacharoff2, Karen Weiss1, Synne Wing Venuti2, Pravin Pant2, Ryan Black2
1US Food and Drug Administration's Safe Use Initiative, Washington, DC, USA, 2Inflexxion, Inc., Newton, MA, USA
54. The distribution of diazepam urinary metabolites in a sample of patients with chronic pain
Samantha O. Luk1, Rabia S. Atayee1,2, Joseph D. Ma1,2, Brookie M. Best1,3, Amadeo J. Pesce4,5
1University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA
55. A survey of ambulatory care pharmacist's perceptions and use of state controlled substance registries
Karen Marlowe1,2, Emily MCCoy1,2
1Auburn University, Auburn, AL, USA, 2University of South Alabama, Mobile, AL, USA
56. Update on the safety of pharmaceutical-grade dimethyl sulfoxide as a penetration enhancer for diclofenac sodium topical solution
Jeffrey Patrick, Karrie Marren
Covidien, Hazelwood, MO, USA
57. Provider adherence to an institution-wide opioid therapy policy for patients with chronic noncancer pain in the primary care setting
Michele Matthews1,2, Alexander Tinios1, Robert Jamison2, Edgar Ross2, Lori Tishler2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Brigham and Women's Hospital, Boston, MA, USA
58. Lifestyle Redesign® for Chronic Headaches
Susan McNulty, Soma Sahai-Srivastava
University of Southern California, Los Angeles, CA, USA
59. Will the FDA's REMS for opioids become an Emerging Solution in Pain (ESP)?
Bronwyn Boyes, Joan Meyer
MediCom Worldwide, Inc., Morrisville, PA, USA
60. Effectiveness of nonpharmacological/noninterventional CBT based treatment for chronic pain
Rick F. Meyers1, Kathy Savicki2, Janice Veehuizen1,2, Ed Daly1, Steven-Tackett Nelson1, Rebecca Ricoy1
1Mid-Valley Pain Clinic, Salem, OR, USA, 2Behavioral Care Network, Salem, OR, USA, 3Oregon Health and Sciences University, Portland, OR, USA
61. A correlative study of the self-reported Ratings Determining Impairment Associated with Pain, from the AMA Guides Fifth Edition, and the clinician-derived Physical Performance Tests on Individuals with polytrauma history and with chronic pain: case series
Armando Miciano1, Jacqueline Derhousoff1, Chad Cross2
1Nevada Rehabilitation Institute, Las Vegas, NV, USA, 2University of Nevada, Las Vegas, NV, USA
62. Direct medical costs of opioid management and the functional status of subjects with polytrauma history >two years and chronic noncancer pain: impact on healthcare utilization and life care planning
Armando Miciano
Nevada Rehabilitation Institute, Las Vegas, NV, USA
63. Quantification of skeletal muscle mass by Bioelectric Impedance Analysis in elderly individuals with chronic nonmalignant pain and in asymptomatic individuals and its relationships among impairments in gait and balance, functional limitations, and disability
Armando Miciano
Nevada Rehabilitation Institute, Las Vegas, NV, USA
64. The functional status due to Pain-Related Impairments, according to the AMA Guides Sixth Edition, and the physical performance status of subjects with a >two-year polytrauma history and with a spine impairment: a descriptive case study
Armando Miciano1, Chad Cross1
1Nevada Rehabilitation Institute, Las Vegas, NV, USA, 2University of Nevada, Las Vegas, NV, USA
65. Determining the functional status, according to the AMA Guides Sixth Edition, Pain-Related Impairment, and physical performance of community-dwelling adults with osteopenia and with lower extremity pain
Armando Miciano
Nevada Rehabilitation Institute, Las Vegas, NV, USA
66. Direct medical costs of pain specialist visits, the multimorbidity burden, pain-related impairment, and the physical performance on subjects with polytrauma history >two years and chronic nonmalignant pain: impact on life care planning
Armando Miciano
Nevada Rehabilitation Institute, Las Vegas, NV, USA
67. Occipital nerve radiofrequency ablation for occipital neuralgia and associated headaches: report of two special medical condition cases
Rafael Miguel, Christopher Russo
Pain Medicine Program, Department of Neurology, University of South Florida, Tampa, Florida, USA
68. Therapeutic monitoring of benzodiazepines in the population of patients treated for pain: current limitations of inoffice immunoassays necessitate testing by mass spectrometry to assure accuracy
Charles Mikel, Murray Rosenthal, Amadeo Pesce
Millennium Research Institute, San Diego, CA, USA
69. Pain Paradox: clinician judgment for assessment and management of risks in chronic opioid therapy
James Miller1, Howard A. Heit2, Douglas Gourlay3, John F. Peppin4, Carol Hampton5, Susan E. Miller1
1Educational Awareness Solutions, Norwalk, CT, USA, 2Georgetown School of Medicine, Fairfax, VA, USA, 3Wasser Pain Management Center, Mount Sinai Hospital, Toronto, ON, Canada, 4The Pain Treatment Centers of the Bluegrass, Lexington, KY, USA, 5Research and Outcomes Institute, South Norwalk, CT, USA
70. Breakthrough cancer pain in patients treated with fentanyl sublingual tablets: posthoc analyses of treatment response
Srinivas Nalamachu1, Richard L. Rauck2, Ann Yellowlees3, Greg Guillory4, Julian Howell4
1Mid America Physiatrists, PA, Leawood, Kansas, USA, 2Carolinas Pain Institute Center for Clinical Research, Winston-Salem, North Carolina, USA, 3Quantics Consulting Ltd, Roslin EH25 9TT, UK, 4ProStrakan, Inc., Bedminster, New Jersey, USA
71. Efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain: a pooled analysis of two studies
Srinivas R. Nalamachu1, Arvind Narayana2, Craig Q. Earl2, Ronghua Yang2, Mark S. Wallace3
1Mid-America Physiatrists, Overland Park, KS, USA, 2Cephalon, Inc., Frazer, PA, USA, 3University of California, San Diego, School of Medicine, La Jolla, CA, USA
72. The National Breakthrough Pain Survey (NBTPS): assessment of quality of life, functioning, and productivity
Arvind Narayana1, Nathaniel Katz2,3, Alicia C. Shillington4, Russell K. Portenoy5
1Cephalon, Inc., Frazer, PA, USA, 2Tufts University School of Medicine, Boston, MA, USA, 3Analgesic Solutions, Natick, MA, USA, 4EPI-Q, Inc., Oak Brook, IL, USA, 5Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY, USA
73. Aberrant drug-related behavior observed during a 12-week open-label study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain
Steven D. Passik1, Craig Q. Earl2, Ronghua Yang2
1Vanderbilt University Medical Center, Nashville, TN, USA, 2Cephalon, Inc., Frazer, PA, USA
74. Exploring the economic impact of a pre-evaluation unit in a multidisciplinary pain clinic
Kenneth L. Kirsh1, Peter Wright1,2, John F. Peppin1,2
1The Pain Treatment Center of the Bluegrass, Lexington, Kentucky, USA, 2Hospice of the Bluegrass, Lexington, Kentucky, USA, 3The University of Kentucky, Lexington, Kentucky, USA
75. Functional assessment of chronic pain patients in a multidisciplinary pain clinic
John F. Peppin1,2, Steve Marcum4, Ashley Baughn3, Kenneth L. Kirsh3
1The Pain Treatment Center of the Bluegrass, Clinical Research Division, Lexington, Kentucky, USA, 2Hospice of the Bluegrass, Lexington, Kentucky, USA, 3The Pain Treatment Center of the Bluegrass, Behavioral Medicine, Lexington, Kentucky, USA, 4The Pain Treatment Center of the Bluegrass, Physical Therapy Department, Lexington, Kentucky, USA
76. Effect of age and sex on the pharmacokinetics and metabolism of oxymorphone extended-release tablets
Joseph V. Pergolizzi1, Matthew S. Wieman2, Errol M. Gould2
1Naples Anesthesia and Pain Associates, Naples, FL, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, PA, USA
77. Safety of oxymorphone extended release with selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors
John H. Peniston1, Susan Potts2, Xiaojun Hu2, Matthew S. Wieman2
1Feasterville Family Health Care Center, Jamison, PA, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, PA, USA
78. Oxymorphone extended release in patients with depression
John H. Peniston1, Susan Potts2, Xiaojun Hu2, Matthew S. Wieman2
1Feasterville Family Health Care Center, Jamison, PA, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, PA, USA
79. Effectiveness of a heated lidocaine/tetracaine topical patch in reducing pain intensity and pain interference associated with myofascial trigger points: results of an open-label pilot study
Richard Rauck1, Michael Busch2, Thomas Marriott2, Michael Smith2, James Heusner2
1Carolinas Pain Institute, Winston-Salem, NC, USA, 2ZARS Pharma, Salt Lake City, UT, USA
80. A model to identify patients at risk for prescription opioid abuse, dependence, and misuse
J. Bradford Rice1, Alan G. White1, Howard G. Birnbaum1, Matthew B. Schiller1, David A. Brown2, Carl L. Roland2
1Analysis Group, Boston, MA, USA, 2Pfizer, Inc., Cary, NC, USA
81. Safety and efficacy of once-daily hydromorphone ER (OROS hydromorphone ER) compared with twice-daily oxycodone CR over 52 weeks in patients with moderate to severe chronic noncancer pain
Ute Richarz1, Sandra Waechter1, Rainer Sabatowski2, Leszek Szczepanski3, Heinrich Binsfeld4
1Janssen-Cilag, Baar, Switzerland, 2University Hospital Carl Gustav Carus, Technical University, Dresden, Germany, 3Wyzsza Szkola Zarzadzania i Administracji, Zamosc, Poland, 4Schmerz-Zentrum am St. Franziskus Hospital Ahlen, Ahlen, Germany
82. Assessing a new educational strategy to improve postoperative pain management after discharge
Gary A. Rich
Adherent Health, Doylestown, PA, USA
83. Physician risk assessment for opioid therapy in patients with chronic pain: results from a national survey
Gregory Salinas1, Jill Foster1, Stephen Burton1, Nancy Roepke1, Debi Susalka1, Kimberly Evanyo2
1CE Outcomes, LLC, Birmingham, AL, USA, 2Janssen Scientific Affairs, LLC, Raritan, NJ, USA
84. Clinician/patient interactions and counseling on opioid use: results from a national survey
Gregory Salinas1, Jill Foster1, Stephen Burton1, Nancy Roepke1, Debi Susalka1, Kimberly Evanyo2
1CE Outcomes, LLC, Birmingham, AL, USA, 2Janssen Scientific Affairs, LLC, Raritan, NJ, USA
85. Concurrent quantification of itch sensation and pain in patients with postherpetic neuralgia by PainVision
Hiroshi Sekiyama1, Kazuo Hanaoka1,2, Takamichi Kogure1, Kenji Azuma1, Masahiko Sumitani1, Yoshitsugu Yamada1
1Department of Anesthesiology, University of Tokyo, Tokyo, Japan, 2Department of Anesthesiology, Tokyo, Japan
86. Assessing the abuse potential of crushed EMBEDA® compared to crushed morphine sulfate controlled-release tablets and placebo in nondependent, recreational opioid users following intranasal administration
Beatrice Setnik1, Jody Cleveland1, Veeraindar Goli1, Naama Levy-Cooperman2, Ira Smith2
1Pfizer Inc., Cary, NC, USA, 2Kendle Early Phase, Toronto, ON, Canada
87. Self reports of prescription opioid misuse, abuse and diversion in a sample of chronic pain patients treated in primary care settings: preliminary findings
Beatrice Setnik, David Brown, Carl Roland
Pfizer Inc., Cary, NC, USA
88. A biomarker panel to assess depression in pain patients
Joseph Shurman1, George Koob2, Rosa Navarro3, Brett Shurman5, Katie Smith4, John Bilello4
1Scripps Memorial Hospital, San Diego, CA, USA, 2Scripps Research Institute, LaJolla, CA, USA, 3Navarro Pain Control Group, Inc., San Diego, CA, USA, 4Ridge Diagnostics, Inc, San Diego, CA, USA, 512401 Wilshire Blvd, Los Angeles, CA, USA
89. Ischemic ulcer pain includes not only nociceptive pain but neuropathic pain components, based on a discriminant function analysis using McGill Pain Questionnaire
Takamichi Kogure1, Masahiko Sumitani1, Arito Yozu2, Hironobu Uematsu3, Satoru Miyauchi4, Yoshitsugu Yamada1
1Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan, 2Department of Rehabilitation Medicine, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, 3Department of Acute Critical Medicine (Anesthesiology), Osaka University, Graduate School of Medicine, Osaka, Japan, 4Kobe Advanced ICT Research Center, National Institute of Communications and Technology, Kobe, Japan
90. Prevalence of CYP450 drug-drug exposures among oxycodone CR patients
Joseph V. Pergolizzi1, Sumedha Labhsetwar2, Kent Summers3, R. Amy Puenpatom3, Rami Ben-Joseph3, Chunmay Fu3
1Naples Anesthesia and Pain Associates, Naples, FL, USA, 2Nema Research Inc., Naples, FL, USA, 3Endo Pharmaceuticals Inc., Chadds Ford, PA, USA
91. Comparison of ECG and Holter monitoring QTc interval measurements in patients with increased risk for QTc prolongation
Arun Sundaram1, Arash Nafissi3, Paul Schweitzer1, Ella Dvorkin1, Peter Homel1, Daniel Feldman1, Russell Portenoy1,2, Ricardo Cruciani1,2
1Dept Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York, USA, 2Dept Neurol & Anesth, Albert Einstein College of Medicine, Bronx, New York, USA, 3Dept P&MR, New York University, New York, New York, USA
92. Usability of an experiential course to educate medical students in proper use of opioids in the treatment of pain
Bradley Tanner, Mary Metcalf, Susan Wilhelm
Clinical Tools, Inc, Chapel Hill, NC, USA
93. Improvement in sleep maintenance and early morning awakenings in adult and elderly patients with insomnia treated with doxepin 3 and 6 mg
Robert Taylor1, Joseph Pergolizzi2, H Heith Durrence3, Brian Dorsey3, Roberta Rogowski1, Thomas Roth1
1NEMA Research Inc., Naples, FL, USA, 2Johns Hopkins University School of Medicine, Baltimore, MD, USA, 3Somaxon Pharmaceuticals, San Diego, CA, USA, 4Henry Ford Sleep Disorders Center, Detroit, MI, USA
94. Consistency of symptom improvement in elderly adults with chronic insomnia treated with doxepin 1 mg, 3 mg, and 6 mg
Robert Taylor1, Joseph Pergolizzi2, H Heith Durrence3, Roberta Rogowski3, Thomas Roth4
1NEMA Research Inc, Naples, FL, USA, 2Johns Hopkins University School of Medicine, Baltimore, MD, USA, 3Somaxon Pharmaceuticals, San Diego, CA, USA, 4Henry Ford Sleep Disorders Center, Detroit, MI, USA
95. Topical corticosteroid administration by pulsed radiofrequency energy
Forest Tennant
Veract Intractable Pain Clinic, West Covina, CA, USA
96. Chorionic gonadotropin initial doses for intractable pain
Forest Tennant
Veract Intractable Pain Clinic, West Covina, CA, USA
97. Endocrine findings and serum opioid levels after 20 years of therapy
Forest Tennant
Veract Intractable Pain Clinic, West Covina, CA, USA
98. Weekly response following a single administration of Qutenza®, an 8% capsaicin patch, in patients with postherpetic neuralgia: results of integrated analyses
Lynn R. Webster1, Gordon Irving2, Miroslav Backonja1, Jeffrey Tobias3, Geertrui F. Vanhove3
1LifeTree Clinical Research, Salt Lake City, UT, USA, 2Swedish Pain Center, Seattle, WA, USA, 3NeurogesX, San Mateo, CA, USA
99. Factors that may affect carisoprodol metabolism by cytochrome P450 (CYP) 2C19 in pain patients using urinary excretion data
Stephanie Tse1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5
1University of California, San Diego (UCSD), Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, >4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA
100. A repeat-dose, steady-state pharmacokinetic evaluation of once-daily hydromorphone ER (OROS hydromorphone ER) in patients with chronic cancer or noncancer pain
Joris Vandenbossche1, Ute Richarz2, Henry Richards3
1Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium, 2Janssen-Cilag, Baar, Switzerland, 3Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, USA
101. Characterization of the pharmacokinetic profile of single-dose once-daily hydromorphone ER (OROS hydromorphone ER) vs IR hydromorphone administered over 24 hours in healthy subjects
Ute Richarz1, Joris Vandenbossche2, Michael Kutch3, Todd Moore4
1Janssen-Cilag, Baar, Switzerland, 2Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium, 3Applied Clinical Intelligence, Bala Cynwyd, PA, USA, 4Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, USA
102. Characterization of the steady-state pharmacokinetic profile of once-daily hydromorphone ER (OROS hydromorphone ER) vs IR hydromorphone in healthy subjects
Ute Richarz1, Joris Vandenbossche2, Michael Kutch3, Todd Moore4
1Janssen-Cilag, Baar, Switzerland, 2Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium, 3Applied Clinical Intelligence, Bala Cynwyd, PA, USA, 4Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, USA
103. TD-1211 demonstrates peripheral selectivity and constipation-relieving effects in patients with opioid-induced constipation
Ross Vickery1, Yu-Ping Li1, Roger Kohler1, Lynn Webster2, Neil Singla3, Oranee Daniels1
1Theravance, Inc., South San Francisco, CA, USA, 2Lifetree Clinical Research, Inc., Salt Lake City, UT, USA, 3Lotus Clinical Research, Inc., Pasadena, CA, USA
104. The impact of health literacy on chronic pain
Julie Waldfogel, Meredith Adams, Robert Hurley
University of Florida, Gainesville, Florida, USA
105. Butrans® (buprenorphine) transdermal system (BTDS) improves health-related quality of life in patients with moderateto-severe chronic low back pain
Aaron Yarlas1, Warren Wen2, Maribeth Kowalski2, Shau Yu Lynch2, Bradley Dain2, Steven Ripa2
1QualityMetric, Inc., Lincoln, RI, USA, 2Purdue Pharma LP, Stamford, CT, USA
106. Butrans® (buprenorphine) Transdermal System (BTDS) improves sleep quality and reduces sleep problems in patients with moderate-to-severe chronic low back pain
Aaron Yarlas1, Warren Wen2, Maribeth Kowalski2, Shau Yu Lynch2, Bradley Dain2, Steven Ripa2
1QualityMetric, Inc., Lincoln, RI, USA, 2Purdue Pharma LP, Stamford, CT, USA
107. Observations on the urinary metabolic profile of codeine in patients with chronic pain
David Yee1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5
1University of California, San Diego (UCSD), Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA
108. painACTION.com: Web-based support to self-manage neuropathic pain
Kevin Zacharoff, Jonas Bromberg, Synne Venuti, Mollie Wood, Dan Surette
Inflexxion, Inc., Newton, MA, USA
109. Survey of healthcare providers on clinical technology and transition to electronic opioid risk assessments
K.L. Zacharoff, S.F. Butler, M. Wood, S. Charity, S. Budman
Inflexxion, Inc, Newton, MA, USA
110. Pharmacokinetic interaction between the opioid-analgesic fentanyl and the CYP3A inhibitor ketoconazole
Victoria Ziesenitz1, Sonja Koenig1, Nina Mahlke2, Gisela Skopp2, Juergen Burhenne1, Gerd Mikus1
1Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany, 2Institute of Legal Medicine, University of Heidelberg, Heidelberg, Germany
111. Observations of oxycodone coprescriptions and nonreported prescription medications in a population of those with chronic pain
Elizabeth Gonzales, Murray Rosenthal, Amadeo Pesce, Charles Mikel, Robert West, Cameron West, Sergey Latyshev, Perla Almazan
Millennium Research Institute, San Diego, USA
112. Variability of meperidine metabolism and excretion in patients with chronic pain
Kathleen Moy1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5
1University of California San Diego (UCSD), Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA

Share:

Related Content